Physician profile
Sheetal M Patel
NPI 1538322623
$2,683.32
in general payments reported to CMS, 2019-2025
42 companies · $761 in 2025
The $761 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.28 · 2020: $115 · 2021: $253 · 2022: $27.57 · 2023: $432 · 2024: $1,054 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,047 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.59 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $191.11 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $178.88 | 2023-2025 | Enhertu, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $168.62 | 2021-2023 | |
| Incyte Corporation | $153.43 | 2023-2024 | Monjuvi, Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $138.53 | 2023-2025 | Vpriv, Ninlaro, Alunbrig |
| Abbvie INC. | $126.68 | 2023-2025 | |
| Sobi, INC | $125.88 | 2024 | |
| Coherus Oncology, INC. | $118.96 | 2021-2025 | Udenyca |
| Pfizer INC. | $114.48 | 2020-2025 | |
| Daiichi Sankyo INC. | $111.82 | 2024-2025 | Injectafer, Enhertu |
| Amgen INC. | $99.95 | 2020 | |
| Gilead Sciences, INC. | $91.39 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $84.26 | 2024-2025 | Keytruda, Lynparza |
| Genzyme Corporation | $81.91 | 2024-2025 | |
| Janssen Biotech, INC. | $77.14 | 2023-2025 | Rybrevant, Talvey, Darzalex |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $62.72 | 2023-2024 | Libtayo |
| Jazz Pharmaceuticals INC. | $60.20 | 2024 | |
| Tempus Ai, INC | $55.29 | 2024 | |
| Eisai INC. | $46.31 | 2024-2025 | |
| Exelixis INC. | $41.28 | 2019 | |
| Genentech USA, INC. | $38.19 | 2025 | Phesgo, Itovebi |
| G1 Therapeutics, INC. | $37.61 | 2023 | Cosela |
| Seagen INC. | $29.91 | 2023 | Tivdak |
| Tersera Therapeutics LLC | $29.79 | 2025 | Zoladex |
| Pharmacyclics LLC, An Abbvie Company | $27.94 | 2023 | Epkinly, Imbruvica |
| Emd Serono, INC. | $27.61 | 2025 | |
| Puma Biotechnology, INC. | $27.57 | 2022 | |
| Karyopharm Therapeutics INC. | $27.52 | 2024 | Xpovio |
| Novocure INC. | $26.82 | 2024 | Optune Lua (Novottf-200t) |
| Adc Therapeutics America, INC. | $26.05 | 2024 | |
| Alexion Pharmaceuticals, INC. | $25.94 | 2024 | Ultomiris |
| Celgene Corporation | $25.48 | 2025 | Opdivo |
| Beone Medicines USA, INC. | $24.85 | 2025 | Tevimbra |
| Lilly USA, LLC | $22.65 | 2025 | Verzenio, Jaypirca |
| Caris Mpi, INC. | $20.87 | 2025 | Mi Cancer Seek |
| Sun Pharmaceutical Industries INC. | $20.40 | 2025 | |
| Glaxosmithkline, LLC. | $20.07 | 2024 | Jemperli, Zejula |
| Bayer Healthcare Pharmaceuticals INC. | $19.67 | 2025 | |
| Array Biopharma INC | $19.44 | 2023 | Lorbrena, Braftovi, Mektovi |
| Immunocore Limited | $19.21 | 2025 | Kimmtrak |
| Springworks Therapeutics, INC. | $18.98 | 2025 | Ogsiveo |
| Stemline Therapeutics INC. | $17.91 | 2023 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheetal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.